Telo Genomics Corp. announced that it has participated in the International Myeloma Society (?IMS?) annual meeting that took place in Athens, Greece during the last week of September 2023. The company presented positive results in assessing minimal residual disease (?MRD?) in multiple myeloma (?MM?).

The data presented demonstrated repeatable sensitivity three-fold higher than what is currently being used in clinical practice. The presented results will be published in the journal of Clinical Lymphoma, Myeloma & Leukemia. Telo's MRD test pioneers an innovative, proprietary and minimally invasive technology with the potential to facilitate MRD assessment in most MM patients.

The test is designed to monitor MM patients' performance post-treatment to predict patients' relapse or to guide an informed decision to terminate maintenance therapy for patients who remain in remission, a critical unmet need in the clinic. The data presented at the IMS meeting represents the initial phase of an ongoing prospective clinical trial to monitor disease progression in post-treatment patients, by measuring and profiling MRD in these patients using Telo's proprietary technology. The clinical trial is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada.